* Zai Lab Ltd reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -71 cents. The mean expectation of six analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -90 cents to -68 cents per share.

* Revenue rose 47.1% to $101.85 million from a year ago; analysts expected $102.24 million.

* Zai Lab Ltd's reported EPS for the quarter was a loss of 40 cents​.

* The company reported a quarterly loss of $41.67 million.

* Zai Lab Ltd shares had risen by 28.8% this quarter and gained 13.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

* In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Zai Lab Ltd is $50.00 This summary was machine generated from LSEG data November 12 at 03:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.78 -0.40 Beat

Jun. 30 2024 -0.71 -0.80 Missed

Mar. 31 2024 -0.92 -0.50 Beat

Dec. 31 2023 -0.86 -1.00 Missed